Immunome Inc. (Nasdaq: IMNM), a biotechnology company that develops innovative and superior targeted cancer therapies, announced today that it has signed a definitive agreement to buy a set of antibody-related assets and materials from Atreca, Inc. (Nasdaq: BCEL).
According to the agreement, Immunome will pay Atreca $5.5 million upfront and up to $7.0 million in clinical development milestones. The deal is subject to customary conditions, including a stockholder vote by Atreca.
“We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients,” stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome.
Immunome is a biotechnology company that aims to develop innovative and superior targeted cancer therapies. Our portfolio uses different drug modalities that match the biology of each target, such as immunotherapies, targeted effectors, radioligand therapies and ADCs.
Gilead Sciences to acquire Immunomedics in a $21 billion deal